Article
Clinical Evidence of Initiating a Very Low Dose of Sacubitril/Valsartan; Beyond the PARADIGM-HF and PIONEER-HF: A Prospective Observational Analysis
2021-05-13
Abstract excerpt
<h4>Aims: </h4> Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We examined the feasibility of initiating sacubitril/valsartan at a very low dose (VLD) in potentially intole...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f3b5df13-000e-5a01-a0d5-69cdf4704f6b
- DOI
- 10.21203/rs.3.rs-512308/v1
